Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
8
80%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
8(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 28 (80.0%)

Trials by Status

terminated110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NCT01100931
completedphase_2

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

NCT01007292
completedphase_2

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

NCT01009775
completedphase_2

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

NCT00818480
terminatedphase_2

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

NCT00498914
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01100931Phase 1

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

Completed
NCT01007292Phase 2

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Completed
NCT01009775Phase 2

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Completed
NCT00818480Phase 2

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Completed
NCT00498914Phase 2

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Terminated
NCT01038804Phase 2

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Completed
NCT00257478Phase 2

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Completed
NCT00281541Phase 2

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Completed
NCT01023386Phase 1

A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer

Completed
NCT00328588Phase 2

LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10